Compugen Announces First-in-Human Trial for COM503 in Advanced Solid Malignancies
ByAinvest
Monday, Oct 6, 2025 7:07 am ET1min read
CGEN--
The trial aims to evaluate the safety and efficacy of COM503 in participants with advanced solid malignancies. Compugen, a pioneer in predictive computational target discovery powered by AI/ML, has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting PVRIG and TIGIT, respectively. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca. GS-0321, previously known as COM503, is a potential first-in-class, high affinity anti-IL-18 binding protein antibody, currently in Phase 1 development and licensed to Gilead.
Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For more information, please contact Yvonne Naughton, Ph.D., Vice President, Head of Investor Relations and Corporate Communications, at ir@cgen.com or +1 (628) 241-0071.
Compugen, a clinical-stage cancer immunotherapy company, announced that a trial in progress of its first-in-human clinical trial assessing anti-IL18BP antibody, COM503, in advanced solid malignancies will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer. The poster presentation will be on Friday, November 7, 2025. Compugen is a pioneer in predictive computational target discovery, powered by AI/ML.
Holon, Israel, September 12, 2025 - Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), a clinical-stage cancer immunotherapy company, has announced that it will present the results of a first-in-human clinical trial assessing the anti-IL18BP antibody, COM503 (GS-0321), at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland. The poster presentation, titled "A First in Human Clinical Trial to Assess the Anti-IL18BP Antibody, COM503 (GS-0321) in Participants with Advanced Solid Malignancies," will be presented by Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest, Grand Rapids, on Friday, November 7, 2025.The trial aims to evaluate the safety and efficacy of COM503 in participants with advanced solid malignancies. Compugen, a pioneer in predictive computational target discovery powered by AI/ML, has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting PVRIG and TIGIT, respectively. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca. GS-0321, previously known as COM503, is a potential first-in-class, high affinity anti-IL-18 binding protein antibody, currently in Phase 1 development and licensed to Gilead.
Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For more information, please contact Yvonne Naughton, Ph.D., Vice President, Head of Investor Relations and Corporate Communications, at ir@cgen.com or +1 (628) 241-0071.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet